Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma

BACKGROUND: Sorafenib has been recommended as the first-line treatment and shown to prolong median overall survival (OS) of patients with advanced unresectable hepatocellular carcinoma (HCC). Recently, a growing amount of research has supported the application of transarterial chemoembolization (TAC...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Transl Med
Autors principals: Zhao, Shoujie, Dou, Weijia, Fan, Qingling, Hu, Jie, Li, Huichen, Zhang, Xiangnan, Zhang, Qian, Liu, Lei
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7290559/
https://ncbi.nlm.nih.gov/pubmed/32566614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2020.02.123
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars